

NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

15 Nov 2021 (#38)

[Click on blue hyperlink for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- PA-20-185 NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- PA-20-184 Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- PA-20-183 Research Project Grant (Parent R01 Clinical Trial Required)
- PA-20-200 NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- PA-20-195 NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- PA-20-194 NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- <u>PA-20-196</u> NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Important Notices

NOT-MH-22-065 Notice of Availability of Pre-Application Webinar Recording and FAQ for RFA-MH-22-100 Effectiveness and Implementation Research for Post-Acute Interventions to Optimize Long-Term Mental Health Outcomes in Low- and Middle-Income Countries. On September 24, 2021, The National Institute of Mental Health (NIMH) Center for Global Mental Health Research (CGMHR) issued the Funding Opportunity Announcement (FOA) RFA-MH-22-100, "Effectiveness and Implementation Research for Post-Acute Interventions to Optimize Long-Term Mental Health Outcomes in Low- and Middle-Income Countries (R34 Clinical Trial Optional)". To assist potential applicants to the above-referenced FOA, NIMH held a Technical Assistance Webinar on October 19, 2021. This Notice alerts applicants to the availability of the recording of this webinar and subsequent Frequently Asked Questions (FAQ). The recording and FAQ are available on the CGMHR website by clicking here.

NOT-CA-22-012 Notice of Correction to PAR-21-035, "Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trials Required)". The purpose of this Notice is to correct the Other Clinical Trials-related Attachments subsection of the PHS Human Subjects and Clinical Trials Information in Application and Submission Information of Funding Opportunity Announcement (FOA) PAR-21-035, "Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trials Required)".

NOT-OD-22-020 Notice of Change to Application Due Dates for PAR-21-281, "Dyadic Interpersonal Processes and Biopsychosocial Outcomes (R01 - Clinical Trials Not Allowed)" This Notice informs potential applicants that, effective immediately, in Funding Opportunity Announcement (FOA) PAR-21-281, "Dyadic Interpersonal Processes and Biopsychosocial Outcomes (R01 - Clinical Trials Not Allowed)", the following section has been modified to reflect changes to due dates for new applications: *March 05, 2022; March 05, 2023*

NOT-MH-22-020 Notice of Intent to Publish a Funding Opportunity Announcement for Improving Uptake and Use of the Dapivirine Vaginal Ring for HIV Prevention (R01 Clinical Trial Optional). The National Institute of Mental Health (NIMH) intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to solicit applications for research on the dapivirine vaginal ring for HIV prevention, including research to: advance understanding of multilevel facilitators and barriers to use of the dapivirine vaginal ring; develop interventions to support uptake and correct and persistent use of the vaginal ring; and test implementation strategies for optimal delivery of the vaginal ring. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. Related Announcements: NOT-MH-22-021 - Notice of Intent to Publish a Funding Opportunity Announcement for Improving Uptake and Use of the Dapivirine Vaginal Ring for HIV Prevention (R21 Clinical Trial Optional) NOT-MH-22-022 - Notice of Intent to Publish a Funding Opportunity Announcement for Improving Uptake and Use of the Dapivirine Vaginal Ring for HIV Prevention (R34 Clinical Trial Optional). Estimated Publication Date of Funding Opportunity Announcement: February 15, 2022 and First Estimated Application Due Date: August 15, 2022.

Notices of Special Interest

NOT-HL-21-030: Heart, Lung, Blood and Sleep Focused Ancillary Studies to Large Ongoing Clinical Studies (Revised). This Notice of Special Interest (NOSI) seeks to expand the breadth of scientific research on the clinical course, prevention and treatment of diseases within the mission of the National Heart, Lung, and Blood Institute (NHLBI) by leveraging ongoing clinical research studies through ancillary studies. The purpose of this NOSI is to invite research project applications to conduct focused ancillary studies to large ongoing clinical trials (including late-stage T4 implementation clinical trials), observational studies, and registries. This NOSI also serves as a replacement for NOT-HL-20-755 (expired as of November 6, 2021). Submit applications for this initiative using one of the following Funding Opportunity Announcements (FOAs) or any reissues of these announcements.

- PA-20-183 NIH Research Project Grant (Parent R01 Clinical Trial Required)
- PA-20-185 NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- PAR-19-274 Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)

Funding Opportunity Announcements (FOA)

1. Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R01 - Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date Hyperlink: PAR-21-353 Type: RC

Application Due Date: February 05, 2022; June 05, 2022 October 05, 2022 through to 2024. Apply by 5:00 PM local time of applicant organization

Funding Opportunity Announcement: This FOA encourages research relevant to the development of novel screening approaches and/or therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as for "high priority" genetic conditions where screening may be possible in the near future. Having an accurate screening test, as well as demonstrating the benefits of early intervention or treatment, are important criteria for including a condition on a newborn screening panel. This FOA defines a "high priority" condition as one where screening is not currently recommended, but infants with the condition would significantly benefit from early identification and treatment. **Companion Funding Opportunities:**

PAR-21-354, RO3 Small Research Grants

PAR-21-355, R21 Exploratory/Developmental Grants

Budget: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Applicants requesting \$500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application and follow the Policy on the Acceptance for Review of Unsolicited Applications that Request \$500,000 or More in Direct Costs